{"id":"https://openalex.org/W4253198702","doi":"https://doi.org/10.1158/1538-7445.am2019-2244","title":"Abstract 2244: DeepIL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy","display_name":"Abstract 2244: DeepIL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4253198702","doi":"https://doi.org/10.1158/1538-7445.am2019-2244"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-2244","doi":"https://doi.org/10.1158/1538-7445.am2019-2244","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-2244","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010258163","display_name":"Elena Geretti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elena Geretti","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103061445","display_name":"Xiaoyan Liang","orcid":"https://orcid.org/0009-0009-9873-4080","observed_orcids":["https://orcid.org/0009-0009-9873-4080"]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoyan Liang","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078804676","display_name":"Jesse Lyons","orcid":"https://orcid.org/0000-0002-9272-4094","observed_orcids":["https://orcid.org/0000-0002-9272-4094"]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jesse Lyons","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002662528","display_name":"Philip D. Bardwell","orcid":"https://orcid.org/0000-0002-3835-255X","observed_orcids":["https://orcid.org/0000-0002-3835-255X"]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip Bardwell","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043754428","display_name":"Santina Caruso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Santina Caruso","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085059704","display_name":"Becker Hewes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Becker Hewes","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109881019","display_name":"Jonathan B. Fitzgerald","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Fitzgerald","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082196069","display_name":"Karsten Sauer","orcid":"https://orcid.org/0000-0002-8355-9429","observed_orcids":["https://orcid.org/0000-0002-8355-9429"]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karsten Sauer","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010338422","display_name":"Thomas  Lars Andresen","orcid":"https://orcid.org/0000-0002-1048-127X","observed_orcids":["https://orcid.org/0000-0002-1048-127X"]},"institutions":[{"id":"https://openalex.org/I4210137081","display_name":"Torque (United States)","ror":"https://ror.org/03sa4ef12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210137081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Andresen","raw_affiliation_strings":["Torque Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Torque Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210137081"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210137081"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"2244","last_page":"2244"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8330000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8330000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.07370000332593918,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0471000000834465,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/il-15","display_name":"IL-15","score":0.9380000233650208},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9330000281333923},{"id":"https://openalex.org/keywords/cancer-immunotherapy-resistance","display_name":"cancer immunotherapy resistance","score":0.7680000066757202},{"id":"https://openalex.org/keywords/tumor-immune-checkpoint","display_name":"tumor immune checkpoint","score":0.4959999918937683},{"id":"https://openalex.org/keywords/cd8-t-cell-expansion","display_name":"CD8+ T cell proliferation","score":0.8169999718666077},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.6909999847412109},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.5519999861717224},{"id":"https://openalex.org/keywords/systemic-toxicity","display_name":"systemic toxicity","score":0.48500001430511475},{"id":"https://openalex.org/keywords/b16f10-melanoma","display_name":"B16F10 melanoma","score":0.8119999766349792},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.6594698429107666},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.6186643242835999},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.556740403175354},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.5315223932266235},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5148760080337524},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.494615763425827},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4858843684196472},{"id":"https://openalex.org/C90375314","wikidata":"https://www.wikidata.org/wiki/Q3537484","display_name":"Adoptive cell transfer","level":4,"score":0.4710262715816498},{"id":"https://openalex.org/C98119934","wikidata":"https://www.wikidata.org/wiki/Q14907167","display_name":"Interleukin 15","level":4,"score":0.43757352232933044},{"id":"https://openalex.org/C128240485","wikidata":"https://www.wikidata.org/wiki/Q786998","display_name":"Autocrine signalling","level":3,"score":0.41519567370414734},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37068110704421997},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.3401463031768799},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3303699195384979},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.31854870915412903},{"id":"https://openalex.org/C74172505","wikidata":"https://www.wikidata.org/wiki/Q194908","display_name":"Interleukin","level":3,"score":0.24085721373558044},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.13769745826721191},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12643560767173767},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07253599166870117},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-2244","doi":"https://doi.org/10.1158/1538-7445.am2019-2244","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-2244","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4313365728","https://openalex.org/W2914930995","https://openalex.org/W3013079331","https://openalex.org/W4297250188","https://openalex.org/W3189195217","https://openalex.org/W2130898753","https://openalex.org/W4313365988","https://openalex.org/W4403905624","https://openalex.org/W2089456457","https://openalex.org/W2886159142"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"Interleukin-15":[2],"(IL-15)":[3],"activates":[4],"and":[5,10,89,95,113,155,205,212,222,228,259,265,275,286,307,345,347,365,395],"expands":[6],"both":[7,284],"CD8+T":[8,145,264],"cells":[9,12,61,77,124,146,317,429],"NK":[11,266],"but":[13],"not":[14],"immunosuppressive":[15],"Tregcells.":[16],"While":[17],"IL-15":[18,35,53,74,121,134,157,165,320,333,338,389],"is":[19,29,54,380],"an":[20],"attractive":[21],"asset":[22],"for":[23,386,447],"cancer":[24],"immunotherapy,":[25],"its":[26],"systemic":[27,36,82,93,210,253],"administration":[28],"limited":[30,107],"by":[31,108,114,137],"toxicities.":[32,97],"To":[33],"limit":[34],"exposure,":[37,211],"we":[38,118],"have":[39],"developed":[40],"DeepTM":[41],"IL-15,":[42],"a":[43,142,276,348,382,397],"multimer":[44],"of":[45,101,139,184,191,239,246,262,291,298,332,355,443],"chemically":[46],"crosslinked":[47],"IL-15/IL-15":[48],"R\u03b1/Fc":[49],"heterodimers":[50],"(IL15-Fc).":[51],"Deep":[52,73,120,133,156,164,319,325,337],"surface":[55],"anchored":[56,159],"to":[57,63,128,160,162,182,226,255,283,434,437],"tumor":[58,202,233,279],"reactive":[59],"T":[60,86,102,110,123,207,316,342,393,428],"prior":[62,181],"adoptive":[64],"cell":[65,87,103,111],"transfer":[66,354],"(ACT).":[67],"This":[68],"novel":[69],"therapeutic":[70],"approach":[71],"enables":[72],"loading":[75,314],"onto":[76],"at":[78],"concentrations":[79],"unachievable":[80],"with":[81,125,141,175,249,318,359,376,400,431],"IL15-Fc,":[83,256],"causes":[84],"autocrine":[85],"activation":[88,344],"expansion,":[90],"yet":[91],"limits":[92],"exposure":[94,254],"associated":[96],"The":[98],"anti-tumor":[99,223,296,368],"activity":[100,224,297,369],"therapies":[104],"has":[105],"been":[106],"insufficient":[109],"expansion":[112,221,261],"checkpoint":[115,360,401,438],"immunosuppression.":[116],"Here,":[117],"combined":[119,358],"primed":[122,427],"PD-L1":[126,287,372,432],"blockade":[127,288,402,433],"overcome":[129,435],"these":[130],"limitations.":[131],"Methods":[132],"was":[135,158,242,362],"synthesized":[136],"incubation":[138],"IL15-Fc":[140,209,247],"crosslinker.":[143],"PMEL":[144,161,167,186,217,241,269,357],"(PMEL)":[147],"were":[148,173],"isolated":[149],"from":[150],"B6.Cg-Thy1a/Cy":[151],"Tg(TcraTcrb)8Rest/J":[152],"mice,activated,":[153],"expanded,":[154],"generate":[163],"Primed":[166,390],"(Deep-15":[168],"PMEL).":[169],"B16-F10":[170,374],"tumor-bearing":[171],"mice":[172],"treated":[174],"cyclophosphamide":[176],"(4":[177],"mg/mouse)":[178],"one":[179],"day":[180],"injection":[183],"107Deep-15":[185],"(carrying":[187],"~":[188],"58":[189],"ug":[190],"IL15-Fc)\u00b1":[192],"anti-PD-L1":[193,292],"antibody":[194],"(10":[195],"mg/kg":[196],"q2w).":[197],"We":[198],"monitored":[199],"mouse":[200],"weight,":[201],"volumes,":[203],"transferred":[204],"endogenous":[206,263],"cells,":[208],"cytokine":[213],"release.":[214],"Results":[215],"Deep-15":[216,240,268,299,356],"showed":[218],"significantly":[219],"improved":[220,294],"compared":[225,282],"PMEL,":[227,250,300],"provided":[229],"long-term":[230],"protection":[231],"against":[232],"re-challenge.":[234],"Importantly,":[235],"the":[236,295,329,371,444],"toxicity":[237,350],"profile":[238],"better":[243],"than":[244],"that":[245],"co-injection":[248],"yielding":[251],"lower":[252],"less":[257],"IFN-\u03b3induction":[258],"no":[260],"cells.":[267],"resulted":[270],"in":[271,302,370,403],"2/10":[272],"partial":[273],"regressions":[274],"statistically":[277],"significant":[278],"growth":[280],"inhibition":[281,361],"vehicle":[285],"alone.":[289],"Co-administration":[290],"further":[293],"resulting":[301],"10/10":[303,377],"Complete":[304],"Regressions":[305],"(CR)":[306],"6/10":[308],"Tumor":[309],"Free":[310],"Survivors.":[311],"Conclusions":[312],"By":[313],"tumor-reactive":[315],"before":[321],"ACT,":[322],"Torque's":[323],"proprietary":[324],"Priming":[326,339],"technology":[327],"leverages":[328],"immune-stimulating":[330],"power":[331],"while":[334],"avoiding":[335],"immunotoxicity.":[336],"promotes":[340],"engrafted":[341],"cell-specific":[343],"proliferation,":[346],"favorable":[349],"profile.":[351],"In":[352],"vivo":[353],"well":[363],"tolerated":[364],"elicited":[366],"remarkable":[367],"refractory":[373],"model,":[375],"CRs.":[378],"Torque":[379],"initiating":[381],"Phase":[383],"I":[384],"trial":[385],"TRQ15-01":[387],"(Deep":[388],"multi-targeted":[391],"human":[392],"cells)":[394],"planning":[396],"combination":[398],"arm":[399],"solid":[404],"tumors.":[405],"Citation":[406],"Format:":[407],"Elena":[408],"Geretti,":[409],"Xiaoyan":[410],"Liang,":[411],"Jesse":[412],"Lyons,":[413],"Philip":[414],"Bardwell,":[415],"Santina":[416],"Caruso,":[417],"Becker":[418],"Hewes,":[419],"Jonathan":[420],"Fitzgerald,":[421],"Karsten":[422],"Sauer,":[423],"Thomas":[424],"Andresen.":[425],"DeepIL-15":[426],"synergize":[430],"resistance":[436],"immunotherapy":[439],"[abstract].":[440],"In:":[441],"Proceedings":[442],"American":[445],"Association":[446],"Cancer":[448,462],"Research":[449],"Annual":[450],"Meeting":[451],"2019;":[452],"2019":[453],"Mar":[454],"29-Apr":[455],"3;":[456],"Atlanta,":[457],"GA.":[458],"Philadelphia":[459],"(PA):":[460],"AACR;":[461],"Res":[463],"2019;79(13":[464],"Suppl):Abstract":[465],"nr":[466],"2244.":[467]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2022-05-12T00:00:00"}